Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Angell

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Science Translational Medicine|February 26, 2016
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasisBernhard Mlecnik, Gabriela Bindea, Amos Kirilovsky, et al.
Science Translational Medicine|March 21, 2014
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patientsBernhard Mlecnik, Gabriela Bindea, Helen K Angell, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket studyMatthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, et al.
Molecular Cancer|December 2, 2025
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancerMingchao Xie, Miljenka Vuko, Shashank Saran, et al.
Cancer Research|June 11, 2015
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized ImmunotherapyPauline Maby, David Tougeron, Mohamad Hamieh, et al.
Frontiers in Immunology|October 8, 2024
Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoringJulie Berthe, Pawan Poudel, Felix J Segerer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2025
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid TumorsLillian L Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez, et al.
Cancer Research Communications|December 18, 2025
Characterisation of the immunogenomic landscape of ovarian cancer uncovers a distinct subset of endometroid tumours associated with high CST2 expression and a favourable prognosisJames Boyle, Jan Zaucha, Felicia Ng, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
The Lancet. Oncology|August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket studySusan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Science Translational Medicine|February 26, 2016
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasisBernhard Mlecnik, Gabriela Bindea, Amos Kirilovsky, et al.
Science Translational Medicine|March 21, 2014
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patientsBernhard Mlecnik, Gabriela Bindea, Helen K Angell, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket studyMatthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, et al.
Molecular Cancer|December 2, 2025
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancerMingchao Xie, Miljenka Vuko, Shashank Saran, et al.
Cancer Research|June 11, 2015
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized ImmunotherapyPauline Maby, David Tougeron, Mohamad Hamieh, et al.
Frontiers in Immunology|October 8, 2024
Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoringJulie Berthe, Pawan Poudel, Felix J Segerer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2025
AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid TumorsLillian L Siu, Sophie Postel-Vinay, Rafael Villanueva-Vázquez, et al.
Cancer Research Communications|December 18, 2025
Characterisation of the immunogenomic landscape of ovarian cancer uncovers a distinct subset of endometroid tumours associated with high CST2 expression and a favourable prognosisJames Boyle, Jan Zaucha, Felicia Ng, et al.
British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.
The Lancet. Oncology|August 11, 2020
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket studySusan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, et al.
Pageof 5